Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its upcoming participation in the Citizens Life Sciences Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation at the event.
The presentation is scheduled for Wednesday, May 7, 2025, at 3:00 pm ET and will take place at the New York Hilton Midtown. Interested parties can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The presentation recording will remain available for 90 days after the event.
Verrica specializes in developing medications for skin diseases that require medical interventions, positioning itself as a key player in the dermatology therapeutics sector.
Verrica Pharmaceuticals (Nasdaq: VRCA), azienda specializzata in terapie dermatologiche, ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference a New York. Il Presidente e CEO dell'azienda, Jayson Rieger, PhD, MBA, terrà una presentazione durante l'evento.
La presentazione è prevista per mercoledì 7 maggio 2025 alle 15:00 ET presso il New York Hilton Midtown. Gli interessati potranno seguire la diretta streaming tramite il link fornito o nella sezione Investors/Presentations & Events del sito di Verrica. La registrazione della presentazione sarà disponibile per 90 giorni dopo l'evento.
Verrica si dedica allo sviluppo di farmaci per malattie della pelle che richiedono interventi medici, affermandosi come un attore chiave nel settore delle terapie dermatologiche.
Verrica Pharmaceuticals (Nasdaq: VRCA), una empresa de terapias dermatológicas, anunció su próxima participación en la Citizens Life Sciences Conference en la ciudad de Nueva York. El presidente y CEO de la compañía, Jayson Rieger, PhD, MBA, ofrecerá una presentación en el evento.
La presentación está programada para el miércoles 7 de mayo de 2025 a las 3:00 pm ET y tendrá lugar en el New York Hilton Midtown. Los interesados podrán acceder a una transmisión en vivo a través del enlace proporcionado o en la sección Investors/Presentations & Events del sitio web de Verrica. La grabación de la presentación estará disponible durante 90 días después del evento.
Verrica se especializa en el desarrollo de medicamentos para enfermedades de la piel que requieren intervenciones médicas, posicionándose como un actor clave en el sector de terapias dermatológicas.
Verrica Pharmaceuticals (나스닥: VRCA)는 피부 치료제 전문 회사로서 뉴욕시에서 열리는 Citizens Life Sciences Conference에 곧 참여할 예정임을 발표했습니다. 회사의 사장 겸 CEO인 Jayson Rieger 박사(MBA 포함)가 행사에서 발표를 진행할 예정입니다.
발표는 2025년 5월 7일 수요일 오후 3시(동부시간)에 뉴욕 힐튼 미드타운에서 열립니다. 관심 있는 분들은 제공된 링크나 Verrica 웹사이트의 Investors/Presentations & Events 섹션을 통해 라이브 웹캐스트를 시청할 수 있습니다. 발표 녹화 영상은 행사 후 90일간 제공됩니다.
Verrica는 의료적 개입이 필요한 피부 질환 치료제를 개발하는 데 주력하며, 피부 치료제 분야에서 중요한 역할을 하고 있습니다.
Verrica Pharmaceuticals (Nasdaq : VRCA), une société spécialisée dans les traitements dermatologiques, a annoncé sa prochaine participation à la Citizens Life Sciences Conference à New York. Le président et CEO de l'entreprise, Jayson Rieger, PhD, MBA, donnera une présentation lors de l'événement.
La présentation est prévue pour le mercredi 7 mai 2025 à 15h00 ET au New York Hilton Midtown. Les intéressés pourront accéder à une diffusion en direct via le lien fourni ou via la section Investors/Presentations & Events du site web de Verrica. L'enregistrement de la présentation restera disponible pendant 90 jours après l'événement.
Verrica se spécialise dans le développement de médicaments pour les maladies de la peau nécessitant des interventions médicales, se positionnant comme un acteur clé dans le secteur des traitements dermatologiques.
Verrica Pharmaceuticals (Nasdaq: VRCA), ein Unternehmen für dermatologische Therapien, gab seine bevorstehende Teilnahme an der Citizens Life Sciences Conference in New York City bekannt. Der Präsident und CEO des Unternehmens, Jayson Rieger, PhD, MBA, wird auf der Veranstaltung eine Präsentation halten.
Die Präsentation ist für Mittwoch, den 7. Mai 2025, um 15:00 Uhr ET im New York Hilton Midtown geplant. Interessierte können die Live-Übertragung über den bereitgestellten Link oder im Bereich Investors/Presentations & Events auf der Website von Verrica verfolgen. Die Aufzeichnung der Präsentation wird 90 Tage nach der Veranstaltung verfügbar sein.
Verrica spezialisiert sich auf die Entwicklung von Medikamenten für Hauterkrankungen, die medizinische Eingriffe erfordern, und positioniert sich als wichtiger Akteur im Bereich der dermatologischen Therapien.
- None.
- None.
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City.
Citizens Life Sciences Conference, May 7-8, 2025
Event details:
Date: Wednesday, May 7, 2025
Time: 3:00 pm ET
Location: New York Hilton Midtown, New York
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) presenting at the Citizens Life Sciences Conference 2025?
How can investors watch Verrica Pharmaceuticals' (VRCA) presentation at the Citizens Life Sciences Conference?
Who is representing Verrica Pharmaceuticals (VRCA) at the 2025 Citizens Life Sciences Conference?
What type of company is Verrica Pharmaceuticals (VRCA)?
Where can investors find the replay of Verrica Pharmaceuticals' (VRCA) Citizens Conference presentation?
